Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury

Overview

About this study

The purpose of this study is to evaluate the efficacy and safety of a single injection of iltamiocel (300 x 10^6 cells) compared to a placebo in the reduction of fecal incontinence episode frequency in adult female participants with chronic fecal incontinence and a history of obstetric anal sphincter injury. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

-Adult female ≥ 18 years of age who has primary symptoms of fecal incontinence (FI) for at least 12 months.
-History of obstetric anal sphincter injury (e.g., episiotomy, perineal tear).
-Failed conservative treatment (e.g., dietary modification, antidiarrheal medications, pelvic floor muscle training, biofeedback) for at least 6 months prior to enrollment.
-Has a Cleveland Clinic Florida Incontinence Score (CCFIS) ≥9 at Baseline.
-Must be willing and able to comply with the study procedures, be mentally competent and able to understand all study requirements, and must agree to read and sign the informed consent form prior to any study-related procedures.

Exclusion Criteria:

-Has an implanted stimulation neuromodulation system (sacral or tibial) and symptoms are unstable as determined by the physician.
-Is pregnant or planning to become pregnant within the next 2 years.
-Has known rectal sensory dysfunction (e.g., hypersensitivity or hyposensitivity).
-Has an obstetric anal sphincter injury (e.g., episiotomy, perineal tear) within 1 year previous to study enrollment.
-Patient BMI ≥ 35.
-Has a history of cancer in the colorectal or pelvic organs within 5 years prior to study enrollment.
-Any cancer that has undergone treatment within the past 12 months. -Has an established diagnosis of inflammatory bowel disease (Crohn's disease, ulcerative colitis) or current intestinal stoma.
-Has grade III/IV hemorrhoids. -Has chronic diarrhea at the time of Screening.
-Has chronic constipation at the time of Screening.
-Has significant pelvic floor prolapse, significant genitourinary prolapse beyond the introitus, significant symptomatic rectocele, or evidence of significant rectal evacuation disorder leading to post-defecatory leakage.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 5/8/2024. Questions regarding updates should be directed to the study team contact.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

William Perry, M.B., Ch.B., M.P.H.

Contact us for the latest status

Contact information:

Summer Auerbach

(507) 422-9153

Auerbach.Summer@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20575398

Mayo Clinic Footer